Frontlight ResearchEarly access
Taking peopleNo phase
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
Key facts
- Who runs it
- Centre for Addiction and Mental Health
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 10 Nov 2022
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groups
- Treatments tested
- CBT
- Record updated
- 20 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patient has been referred to or intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in group psychotherapy)
- Able to communicate and provide informed consent in English
- 18 years of age or older
- Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to the eligibility and task-based assessments
- Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group)
- Meets criteria for risky drinking, defined as > 10 drinks per week for females and > 15 drinks per week for males on average over the past 30 days (AUD group) or daily or near-daily cannabis use over the past 30 days, defined as ≥ 4 days of cannabis use per week on average (CUD group)
Who cannot take part
- Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in groups (e.g. active fentanyl use)
- Active suicidal ideation at time of assessment
- Suicide attempt within the past month
- Enrollment in another study that conflicts with the procedures or scientific integrity of this study
- Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This 2-arm study will recruit participants with 1) alcohol use disorder and 2) cannabis use disorder for a 12-week cognitive behavioral therapy, following a thorough baseline assessments on executive function, incentive salience, and negative emotionality.
The 2 groups in the trial
- Alcohol Use DisorderOther group
Participants will be treated with 12 weeks of CBT for AUD (group therapy) and have the option to receive evidence-based pharmacotherapy for AUD guided by a pharmacotherapy algorithm.
Treatment: CBT
- Cannabis Use DisorderOther group
Participants will be treated with 12 weeks of CBT + motivational enhancement therapy for CUD (group therapy).
Treatment: CBT
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 20 March 2026